Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (14)

2024

  1. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

2022

  1. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission

    Medicina Clinica

  2. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

  3. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association

    JHEP Reports, Vol. 4, Núm. 12

2021

  1. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  2. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  3. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis

    CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 50-62

2020

  1. A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL

    Digestive and Liver Disease, Vol. 52, Núm. 8, pp. 857-861

  2. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

    Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884

2017

  1. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases

    Future Oncology, Vol. 13, Núm. 23, pp. 2065-2082

2011

  1. Research reporting standards for radioembolization of hepatic malignancies

    Journal of Vascular and Interventional Radiology, Vol. 22, Núm. 3, pp. 265-278

2009

  1. Diagnóstico y tratamiento del carcinoma hepatocelular

    Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287